Back

Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - SGLT2i Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Ahmed K Awad

University of Texas health sciences, Texas City (United States of America)

4 More presentations in this session

Presentation thumbnail
Cardiac sodium/hydrogen exchanger (NHE11) as a novel potential target for SGLT2i in heart failure
Doctor I. Gimenez Escamilla (Valencia, ES)
Abstract Slides
Presentation thumbnail
SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction
Doctor R. Tarantini (Utrecht, NL)
Abstract Slides
Presentation thumbnail
The comparison of composite end-points between SGLT-2 inhibitors and placebo in diabetic patients with heart failure with mildly reduced ejection fraction: a meta-analysis of the literature
Associate Professor T. Cinar (Istanbul, TR)
Abstract Slides
Presentation thumbnail
SGLT2i uptake among heart failure patients with reduced ejection fraction: ongoing prescriber hesitancy and how to address this.
Doctor B. Soh (Galway, IE)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - SGLT2i

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
Expert panel discussion and Q&A

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources